A Phase 1 interventional study of Abatacept in Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb. Completed at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-07.
Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies testing abatacept in Arthritis, Rheumatoid — 3 open to participants now, 4 under way, 3 of them phase 3. Abatacept · Arthritis, Rheumatoid.
Among the 63 studies testing abatacept in Arthritis, Rheumatoid, this one is the 27th largest by enrollment, is one of 4 that started in 2018, is one of 8 in phase 1, and was the 52nd registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →3 of the 63 studies testing abatacept in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Hospital, Montpellier · Sites in France, Monaco
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
Abatacept: first FDA approval 2005 (ORENCIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 12 · Phase 3 27 · Phase 4 16
First in 2000; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 140 is above the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 119 across the 63 interventional studies. Of the 46 that completed or were terminated, 32 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 63 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb: 4 open now, 8 under way, 2 of them phase 3. Of 82 finished, 31 (38%) have results posted.
Among the 92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb, this one is the 25th largest by enrollment of the 58 interventional ones that give a count, is one of 3 that started in 2018, is one of 19 in phase 1, and was the 82nd registered.
Bristol-Myers Squibb’s Arthritis, Rheumatoid studies by the year they started, since 2000.
1 of the studies testing abatacept in Arthritis, Rheumatoid that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05428488Phase 3University Hospital, MontpellierEfficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 63 studies testing abatacept in Arthritis, Rheumatoid, from their registry updates:
Among Bristol-Myers Squibb’s 92 in Arthritis, Rheumatoid:
This tab as a report to print or save as PDF → With an account.
The main objective of this study is to compare the pharmacokinetics (PK) of the abatacept drug product converted from drug substance by a new drug substance process (Treatment A) relative to the current drug substance process (Treatment B) following a single dose (750 mg) intravenous (IV) infusion in healthy participants.
Participants will be admitted to the clinical facility the day prior to dosing (Day -1) and will be confined until at least 24 hours post-dose. On Day 1, eligible participants will be randomized in a 1:1 ratio to either Treatment A or Treatment B. The randomization will be stratified by weight categories: >= 60 to \< 70 kg, >= 70 to \< 80 kg, >= 80 to \< 90 kg, and >= 90 to \<= 100 kg.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive abatacept at a single dose of 750 mg as IV infusion on Day 1 converted from drug substance by a new process.
Drug: Abatacept
Participants will receive abatacept at a single dose 750 mg as IV infusion on Day 1 converted from drug substance by converted from drug substance by the current process.
Drug: Abatacept
Participants will receive abatacept at a single dose 750 mg as IV infusion.
Maximum Observed Serum Concentration (Cmax)
Maximum Observed Serum Concentration
Time frame: From drug administration to 70 days following drug administration
Area Under the Curve AUC(INF)
Area under the serum concentration-time curve from time zero extrapolated to infinity
Time frame: From drug administration to 70 days following drug administration
Time of Maximum Observed Serum Concentration (Tmax)
Time of maximum observed serum concentration
Time frame: From drug administration to 70 days following drug administration
Area Under the Curve AUC(0-T)
Area under the serum concentration-time curve from zero to the last time of the last quantifiable concentration
Time frame: From drug administration to 70 days following drug administration
Area Under the Curve AUC(0-28)
Area under the serum concentration-time curve from time zero to 28 days after dosing
Time frame: From drug administration to 70 days following drug administration
Total Body Clearance (CLT)
Total body clearance
Time frame: From drug administration to 70 days following drug administration
Volume of Distribution at Steady-State (Vss)
Volume of distribution at steady-state
Time frame: From drug administration to 70 days following drug administration
Terminal Phase Elimination Half-life (T-HALF)
Terminal phase elimination half-life in serum
Time frame: From drug administration to 70 days following drug administration
Number of Participants Experiencing Positive Immunogenicity Response to Abatacept
Positive immunogenicity response to Abatacept was defined if one of the following criteria was met: 1. missing baseline immunogenicity measurement and a positive, post-baseline, laboratory-reported immunogenicity response; 2. a negative laboratory-reported baseline immunogenicity response and a positive, post-baseline, laboratory-reported response; 3. a positive, laboratory-reported, baseline immunogenicity response and a positive, post-baseline, laboratory-reported immunogenicity response with a titer value greater than the baseline titer value.
Time frame: From Day 1 (Predose) to Day 71 (Study Discharge), assessed at day 1, day 29, day 57 and day 71
Number of Participants Experiencing Adverse Events
Number of participants experiencing different types of Adverse Events (AEs). Peri-infusional AEs: occurring during the 30 minute study drug infusion period Post-infusional AEs: occurring within 24 hours post drug infusion
Time frame: From drug administration to 56 days following drug administration
Change From Baseline in Blood Pressure
Mean Change from Baseline in systolic and diastolic blood pressure values
Time frame: From baseline (last result before start of study medication) to 70 days after start of study medication
Change From Baseline in Heart Rate
Mean Change from Baseline in heart rate values
Time frame: From baseline (last result before start of study medication) to 70 days after start of study medication
Change From Baseline in Respiration Rate
Mean Change from Baseline in respiration rate values
Time frame: From baseline (last result before start of study medication) to 70 days after start of study medication
Change From Baseline in Body Temperature
Mean Change from Baseline in body temperature values
Time frame: From baseline (last result before start of study medication) to 70 days after start of study medication
Change From Baseline in Electrocardiogram (ECG) Parameters
Mean Change from Baseline in ECG parameters, including PR interval, QRS interval, QT interval, and QTC Fridericia
Time frame: From baseline (last result before start of study medication) to 70 days after start of study medication
Number of Participants Experiencing Clinically Significant Physical Examination Abnormalities
Number of participants experiencing clinically significant physical examination abnormal findings
Time frame: From the pre-treatment period to 70 days after start of study medication (approximately 100 days)
Change From Baseline in Laboratory Test Results - Hematology 1
Mean Change from Baseline in laboratory test results - Hematology parameters 1
Time frame: From baseline (last result before start of study medication) to 70 days after start of study medication
Change From Baseline in Laboratory Test Results - Hematology 2
Mean Change from Baseline in laboratory test results - Hematology parameters 2
Time frame: From baseline (last result before start of study medication) to 70 days after start of study medication
Change From Baseline in Laboratory Test Results - Hematology 3
Mean Change from Baseline in laboratory test results - Hematocrit
Time frame: From baseline (last result before start of study medication) to 70 days after start of study medication
Change From Baseline in Laboratory Test Results - Chemistry 1
Mean Change from Baseline in laboratory test results - Chemistry parameters 1
Time frame: From baseline (last result before start of study medication) to 70 days after start of study medication
Change From Baseline in Laboratory Test Results - Chemistry 2
Mean Change from Baseline in laboratory test results - Chemistry parameters 2
Time frame: From baseline (last result before start of study medication) to 70 days after start of study medication
Change From Baseline in Laboratory Test Results - Chemistry 3
Mean Change from Baseline in laboratory test results - Chemistry parameters 3
Time frame: From baseline (last result before start of study medication) to 70 days after start of study medication
Change From Baseline in Laboratory Test Results -Hematology and Chemistry 4
Mean Change from Baseline in laboratory test results - hematology and chemistry parameters 4
Time frame: From baseline (last result before start of study medication) to 70 days after start of study medication
| Milestone | Cohort A (New Process) | Cohort B (Current Process) |
|---|---|---|
| Started | 70 | 70 |
| Completed | 66 | 67 |
| Not completed | 4 | 3 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Consent withdrawal | 0 | 1 |
| Withdrew: Lost to follow-up | 3 | 2 |
Maximum Observed Serum Concentration
| ug/mL | Cohort A (New Process) | Cohort B (Current Process) |
|---|---|---|
| Maximum Observed Serum Concentration (Cmax) | 237.0341 ± 26 | 236.2882 ± 23 |
Area under the serum concentration-time curve from time zero extrapolated to infinity
| ug*h/mL | Cohort A (New Process) | Cohort B (Current Process) |
|---|---|---|
| Area Under the Curve AUC(INF) | 35693.8 ± 22 | 38254.6 ± 16 |
Time of maximum observed serum concentration
| Hours | Cohort A (New Process) | Cohort B (Current Process) |
|---|---|---|
| Time of Maximum Observed Serum Concentration (Tmax) | 1.000 (0.47 to 24.00) | 1.000 (0.25 to 24.00) |
Area under the serum concentration-time curve from zero to the last time of the last quantifiable concentration
| ug*h/mL | Cohort A (New Process) | Cohort B (Current Process) |
|---|---|---|
| Area Under the Curve AUC(0-T) | 34473.2 ± 22 | 36671.6 ± 16 |
Area under the serum concentration-time curve from time zero to 28 days after dosing
| ug*h/mL | Cohort A (New Process) | Cohort B (Current Process) |
|---|---|---|
| Area Under the Curve AUC(0-28) | 28597.9 ± 20 | 29765.7 ± 15 |
Total body clearance
| mL/h/Kg | Cohort A (New Process) | Cohort B (Current Process) |
|---|---|---|
| Total Body Clearance (CLT) | 0.2642 ± 21 | 0.2445 ± 17 |
Volume of distribution at steady-state
| L/Kg | Cohort A (New Process) | Cohort B (Current Process) |
|---|---|---|
| Volume of Distribution at Steady-State (Vss) | 0.10444 ± 21 | 0.10462 ± 21 |
Terminal phase elimination half-life in serum
| Hours | Cohort A (New Process) | Cohort B (Current Process) |
|---|---|---|
| Terminal Phase Elimination Half-life (T-HALF) | 357.464 ± 78.6519 | 369.425 ± 76.0162 |
Positive immunogenicity response to Abatacept was defined if one of the following criteria was met: 1. missing baseline immunogenicity measurement and a positive, post-baseline, laboratory-reported immunogenicity response; 2. a negative laboratory-reported baseline immunogenicity response and a positive, post-baseline, laboratory-reported response; 3. a positive, laboratory-reported, baseline immunogenicity response and a positive, post-baseline, laboratory-reported immunogenicity response with a titer value greater than the baseline titer value.
| Participants | Cohort A (New Process) | Cohort B (Current Process) |
|---|---|---|
| Number of Participants Experiencing Positive Immunogenicity Response to Abatacept | 14 | 11 |
Number of participants experiencing different types of Adverse Events (AEs). Peri-infusional AEs: occurring during the 30 minute study drug infusion period Post-infusional AEs: occurring within 24 hours post drug infusion
| Participants | Cohort A (New Process) | Cohort B (Current Process) |
|---|---|---|
| Participants with at least 1 Adverse Event | 20 | 18 |
| Participants with at least 1 peri-infusional Adverse Event | 1 | 2 |
| Participants with at least 1 post-infusional Adverse Event | 4 | 3 |
| Participants with Adverse Event related to study drug | 8 | 7 |
| Death | 0 | 0 |
| Serious Adverse Events (SAEs) | 0 | 0 |
| Adverse Events leading to discontinuation | 0 | 0 |
Mean Change from Baseline in systolic and diastolic blood pressure values
| mmHg | Cohort A (New Process) | Cohort B (Current Process) |
|---|---|---|
| Systolic Blood Pressure | -0.3 ± 12.21 | 2.0 ± 10.72 |
| Diastolic Blood Pressure | -0.8 ± 7.69 | -0.7 ± 8.52 |
Mean Change from Baseline in heart rate values
| bpm | Cohort A (New Process) | Cohort B (Current Process) |
|---|---|---|
| Change From Baseline in Heart Rate | 1.6 ± 9.99 | 0 ± 9.34 |
Mean Change from Baseline in respiration rate values
| breath/min | Cohort A (New Process) | Cohort B (Current Process) |
|---|---|---|
| Change From Baseline in Respiration Rate | 1.0 ± 3.27 | 0.5 ± 3.63 |
Mean Change from Baseline in body temperature values
| C | Cohort A (New Process) | Cohort B (Current Process) |
|---|---|---|
| Change From Baseline in Body Temperature | -0.01 ± 0.486 | -0.06 ± 0.392 |
Mean Change from Baseline in ECG parameters, including PR interval, QRS interval, QT interval, and QTC Fridericia
| msec | Cohort A (New Process) | Cohort B (Current Process) |
|---|---|---|
| PR Interval | 1.6 ± 17.66 | -1.8 ± 10.49 |
| QRS Interval | 1.6 ± 5.70 | -0.0 ± 5.45 |
| QT Interval | -1.1 ± 22.53 | -2.1 ± 17.28 |
| QTC Fridericia | 1.4 ± 13.20 | 0.5 ± 12.70 |
Number of participants experiencing clinically significant physical examination abnormal findings
| Participants | Cohort A (New Process) | Cohort B (Current Process) |
|---|---|---|
| Number of Participants Experiencing Clinically Significant Physical Examination Abnormalities | 0 | 0 |
Mean Change from Baseline in laboratory test results - Hematology parameters 1
| x10*9 cells/L | Cohort A (New Process) | Cohort B (Current Process) |
|---|---|---|
| Platelet Count | 3.9 ± 30.99 | -1.6 ± 31.81 |
| Basophils (absolute) | -0.026 ± 0.0741 | -0.015 ± 0.0292 |
| Eosinophils (absolute) | -0.006 ± 0.1006 | 0.012 ± 0.012 |
| Leukocytes | 0.09 ± 1.154 | -0.07 ± 1.225 |
| Lymphocytes (absolute) | 0.073 ± 0.5086 | -0.028 ± 0.3162 |
| Monocytes (absolute) | -0.045 ± 0.1163 | -0.033 ± 0.1453 |
| Neutrophils (absolute) | 0.083 ± 0.9523 | -0.011 ± 1.0654 |
Mean Change from Baseline in laboratory test results - Hematology parameters 2
| Fraction | Cohort A (New Process) | Cohort B (Current Process) |
|---|---|---|
| Basophils (relative) | -0.0034 ± 0.00779 | -0.0023 ± 0.00462 |
| Eosinophils (relative) | -0.0008 ± 0.01712 | 0.0024 ± 0.01372 |
| Lymphocytes (relative) | 0.0107 ± 0.07609 | 0.0019 ± 0.06250 |
| Monocytes (relative) | -0.0073 ± 0.01389 | -0.0041 ± 0.02072 |
| Neutrophils (relative) | 0.0008 ± 0.08609 | 0.0021 ± 0.07425 |
Mean Change from Baseline in laboratory test results - Hematocrit
| Proportion of Blood Volume | Cohort A (New Process) | Cohort B (Current Process) |
|---|---|---|
| Change From Baseline in Laboratory Test Results - Hematology 3 | -0.0017 ± 0.01845 | 0.0014 ± 0.01767 |
Mean Change from Baseline in laboratory test results - Chemistry parameters 1
| U/L | Cohort A (New Process) | Cohort B (Current Process) |
|---|---|---|
| Alanine Aminotransferase (ALT) | 0.6 ± 9.01 | -1.3 ± 8.50 |
| Alkaline Phosphatase (ALP) | -3.0 ± 7.52 | -0.4 ± 8.86 |
| Aspartate Aminotransferase (AST) | 1.1 ± 15.89 | -1.1 ± 4.11 |
| Lactate Dehydrogenase (LD) | 1.4 ± 47.60 | -3.2 ± 18.30 |
Mean Change from Baseline in laboratory test results - Chemistry parameters 2
| umol/L | Cohort A (New Process) | Cohort B (Current Process) |
|---|---|---|
| Bilirubin, Direct | -0.01 ± 0.804 | -0.09 ± 0.759 |
| Bilirubin, Total | -0.25 ± 3.467 | -0.54 ± 3.297 |
| Creatinine | -2.2 ± 9.72 | -1.5 ± 8.58 |
Mean Change from Baseline in laboratory test results - Chemistry parameters 3
| mmol/L | Cohort A (New Process) | Cohort B (Current Process) |
|---|---|---|
| Blood Urea Nitrogen | 0.29 ± 1.264 | 0.12 ± 1.125 |
| Calcium, Total | -0.027 ± 0.0809 | -0.012 ± 0.0787 |
| Chloride, Serum | 0.4 ± 1.83 | -0.1 ± 2.01 |
| Magnesium, Serum | -0.011 ± 0.0610 | -0.015 ± 0.0666 |
| Phosphorus, Inorganic | -0.010 ± 0.1537 | -0.040 ± 0.1431 |
| Potassium, Serum | -0.13 ± 0.266 | -0.23 ± 0.311 |
| Sodium, Serum | -0.1 ± 2.22 | -0.2 ± 2.09 |
| Glucose, Serum | 0.04 ± 0.516 | 0.04 ± 0.383 |
| Uric Acid | 0.006 ± 0.0425 | 0.004 ± 0.0341 |
Mean Change from Baseline in laboratory test results - hematology and chemistry parameters 4
| g/L | Cohort A (New Process) | Cohort B (Current Process) |
|---|---|---|
| Hemoglobin (g/L) | -0.6 ± 6.06 | 0.4 ± 5.57 |
| Albumin (g/L) | -0.9 ± 2.53 | -0.3 ± 2.39 |
| Protein, Total (g/L) | -1.2 ± 4.50 | -0.4 ± 4.32 |
Collected over From drug administration to 70 days following drug administration. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A (New Process) | 0/70 (0%) | 0/70 (0%) | 6/70 (8.6%) |
| Cohort B (Current Process) | 0/70 (0%) | 0/70 (0%) | 3/70 (4.3%) |
| Event | Cohort A (New Process) | Cohort B (Current Process) |
|---|---|---|
| NasopharyngitisInfections and infestations | 6/70 | 3/70 |
| Age, Continuous(Years) | Cohort A (New Process) | Cohort B (Current Process) | Total |
|---|---|---|---|
| Mean | 36.4 ± 9.29 | 36.6 ± 9.37 | 36.5 ± 9.30 |
| Sex: Female, Male(Participants) | Cohort A (New Process) | Cohort B (Current Process) | Total |
|---|---|---|---|
| Female | 29 | 26 | 55 |
| Male | 41 | 44 | 85 |
| Ethnicity (NIH/OMB)(Participants) | Cohort A (New Process) | Cohort B (Current Process) | Total |
|---|---|---|---|
| Hispanic or Latino | 40 | 44 | 84 |
| Not Hispanic or Latino | 30 | 26 | 56 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort A (New Process) | Cohort B (Current Process) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 2 |
| Asian | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 22 | 29 | 51 |
| White | 45 | 39 | 84 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Nov 2018 to primary completion in Apr 2019, 4 months.
Results were first posted in Jan 2021, 1 year 9 months after primary completion.
Of 128 industry-sponsored phase 1 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 32. This study's 4 months is below that.
Counting every sponsor, half of 148 studies reached it within 16 months; a quarter within 5 and three quarters within 32.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abatacept